ArticleClinical kidney journal2026
Impact of RAAS blockers on serum potassium and mortality in a large dialysis cohort: a longitudinal analysis.
Article in Clinical kidney journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Renin-angiotensin-aldosterone system inhibitors (RAASIs) are widely used antihypertensive drugs. Due to the hyperkalaemic effect, previous 2012 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines discouraged RAASI use in patients with severe chronic kidney disease (CKD). However, due to the recently discovered cardioprotective and nephroprotective effects, the 2022 KDIGO guidelines suggest their use in CKD stage 4-5. To our knowledge, few studies have explored the use of RAASIs in dialysis patients. This study aims to evaluate the impact of RAASIs on kalaemia and on mortality in a large sample of dialysis patients. Methods: We included 4764 dialysis patients from the Sicilian Registry of Nephrology, Dialysis and Transplantation. The longitudinal association between RAASI intake and serum potassium was analysed by univariate and multivariate linear mixed models. The survival models were computed through univariate and multivariate Cox models and Cox models with mixed effects. Results: The study included 4764 patients, of whom 1207 (25%) were treated with RAASis. Multivariate longitudinal models showed a direct association between RAASI intake and serum potassium {adjusted β = 0.10 [95% confidence interval (CI) 0.05-0.15], Conclusions: In the present study we found, in a large cohort of dialysis patients, an independent, direct association between RAASIs and serum potassium. However, no association was found between RAASI intake and mortality. Although specific randomized controlled trials are needed to confirm our findings, RAASI intake did not seem to have a negative impact on patients' survival, thus suggesting a re-evaluation of RAASI use in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.